Cyagen is proud to attend the 2025 Annual Conference of the Chinese Antibody Society (CAS) on May 10 at the Boston Marriott Cambridge. Visit Booth #5 to explore how our HUGO-Ab™ next-generation humanized mouse models are propelling innovation in bispecific antibodies, antibody-drug conjugates (ADCs), nanobodies, and beyond.

Our experts will be on-site to share how Cyagen's HUGO-Ab™ Mice and CRO platforms empower cutting-edge therapeutic antibody discovery and development – from early target validation to clinical candidate identification.

2025 Annual Conference of the Chinese Antibody Society (CAS)

• Cyagen Booth: 5
• Dates: May 10, 2025
• Location: Boston Marriott Cambridge | Boston, Massachusetts

Featured Attendee

• Dr. Qiming Wang, Cyagen (Director of Product Strategy & Strategic Partnerships)
  
  

Visit us to learn how HUGO-Ab™ Mice - HUGO-Mab, HUGO-Light, HUGO-Nano - Are Revolutionizing Antibody Drug Discovery.

Revolutionizing Antibody Discovery with HUGO-Ab™:

Breakthrough Models for Bispecifics, ADCs, and Nanobody Therapeutics

• HUGO-Mab™: Fully human monoclonal antibody mice offering rich antibody sequence diversity and direct generation of high-affinity molecules—no humanization required.
  
• HUGO-Light™: Fully human common light chain mice optimized for bispecific antibody development, solving light chain mispairing and enhancing correct assembly of bispecific formats like KiH (Knob-into-Hole).
  
• HUGO-Nano™: Fully human nanobody mice for rapid discovery of high-affinity, low-immunogenicity nanobodies with broad application potential across ADCs, bispecifics, and CAR-T therapies.
  
• HUGO-eKO™: Enhanced immune response mice that improve success rates in antibody screening, particularly for difficult-to-target antigens.
  
  

Together, these platforms accelerate discovery pipelines across next-generation antibody modalities.

Request a Free Project Consultation

Meet with our team during CAS 2025 to discuss how Cyagen’s integrated solutions can fast-track your antibody engineering, bispecific, ADC, or cell and gene therapy (CGT) projects.

Book Your In-Person Meeting>>

Contact Us for a Free CAM/CGT Consultation 

About Cyagen

Founded in 2006, Cyagen is a global provider of genetically modified rodent models and innovative cell and gene therapy (CGT) solutions for research and development (R&D), including: disease model development, AAV discovery, drug efficacy studies, and more. The company has established extensive cooperations with scientists and institutions in more than 100 countries, leading to the publication of over 6,300 academic articles, many of which were in the three major journals of CNS (Cell, Nature, Science). From its robust foundation in animal model development, to implementation of artificial intelligence (AI)-powered tools for data analysis and therapeutic discoveries, Cyagen provides one-stop solutions for accelerating basic research and new drug R&D with our unique offering of models, data, algorithms, and services.